Department of Clinical Oncology, Ain Shams University, 17 Abbas Akkad street extension, Nasr City, Cairo, 11371, Egypt.
J Cancer Res Clin Oncol. 2012 Sep;138(9):1487-92. doi: 10.1007/s00432-012-1229-8. Epub 2012 Apr 22.
This study was conducted to test the efficacy and toxicity of cetuximab and irinotecan as a biweekly regimen in treatment of elderly patients with metastatic colorectal cancer (mCRC).
Forty-nine elderly patients (≥65 years) with mCRC who progressed after at least one previous line of treatment were enrolled into this study from May 2008 to January 2011. All recruited patients received cetuximab 500 mg/m(2) and irinotecan 180 mg/m(2) every 2 weeks.
Thirty-seven patients (76 %) were men, and 76 % of patients had colonic cancer in origin. Median age was 69 years. Median overall survival time was 7 months, and median progression-free survival was 4 months. Grade 3-4 skin rash occurred in 20 % of patients, grade 3-4 diarrhea in 18 % of patients, and neutropenia in 28 % of patients.
Cetuximab combined with irinotecan when administered biweekly is safe and effective for treatment of pretreated elderly patients with mCRC.
本研究旨在检验西妥昔单抗联合伊立替康双周方案治疗老年转移性结直肠癌（mCRC）患者的疗效和毒性。
本研究纳入 2008 年 5 月至 2011 年 1 月期间，49 例接受至少一线治疗后进展的老年 mCRC 患者。所有入组患者均接受西妥昔单抗 500mg/m²和伊立替康 180mg/m²，每 2 周 1 次。
37 例患者（76%）为男性，76%的患者结直肠癌原发于结肠。中位年龄为 69 岁。中位总生存期为 7 个月，中位无进展生存期为 4 个月。3-4 级皮疹发生率为 20%，3-4 级腹泻发生率为 18%，中性粒细胞减少发生率为 28%。
西妥昔单抗联合伊立替康双周方案治疗老年 mCRC 患者，疗效确切，安全性良好。
